NewsRamp Psychedelics Podcast
Explore the emerging world of psychedelics with the 'NewsRamp Psychedelics Podcast.' This podcast delivers the latest news and insights from NewsRamp.com, focusing on research developments, therapeutic applications, and regulatory changes in the psychedelics field. Stay informed on the groundbreaking advancements in this evolving industry.
Episodes
Advancing FDA-Designated Therapies: NRx Pharmaceuticals Collaborates with IBN for Corporate Communications Strategy
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) partners with IBN to enhance investor awareness as it progresses with FDA-designated therapies NRX-100 and NRX-101 for suicidal depression, chronic pain, and PTSD. The company's NMDA platform shows promise in treating central nervous system disorders, with plans for an NDA filing for NRX-100 and a public spin-out of subsidiary HOPE Therapeutics. Stay updated on NRXP developments at https://ibn.fm/NRXP
Published: 2025-06-25 09:32:56
Duration: 00:01:52
Psyence Biomedical Chief to Speak at Psychedelic Science 2025 Conference
Mary-Elizabeth Gifford, Chief of Global Impact at Psyence Biomedical Ltd., will be a featured speaker at Psychedelic Science 2025, discussing business ethics in the realm of psychedelic research. Psyence Biomedical is a Nasdaq-listed biopharma company focusing on nature-derived psilocybin medicine for FDA approval.
Published: 2025-06-18 18:15:12
Duration: 00:02:01
Advancements in Cybin Inc.'s Phase 3 Psychedelic Therapeutics Program
Cybin Inc. provided an update on its Phase 3 Psychedelic Therapeutics Program, highlighting progress in the clinical pipeline, with the lead candidate CYB003 advancing into Phase 3 development. CEO Doug Drysdale expressed confidence in the company's IP portfolio and clinical strategy, noting positive shifts in regulatory sentiment as a key factor in expediting the review process. Cybin is focused on creating safe and effective psychedelic-based therapeutics for mental health conditions like major depressive disorder and generalized anxiety disorder.
Published: 2025-06-13 09:53:28
Duration: 00:02:02
Innovations in Psychedelic Therapeutics: Updates from Cybin Inc., NRx Pharmaceuticals Inc., and Silo Pharma Inc.
Cybin Inc. CEO Doug Drysdale will be speaking at the H.C. Wainwright Neuro Perspectives Conference and the Psychedelic Science 2025 Conference, highlighting the company's focus on developing psychedelic-based therapeutics for mental health conditions. Meanwhile, NRx Pharmaceuticals Inc. has filed an application for a preservative-free ketamine formulation to address the shortage of ketamine in the U.S., and Silo Pharma Inc. has received a patent related to biomarkers for evaluating prophylactic treatments for stress-induced affective disorders, strengthening its position in the field of psychedelic therapeutics.
Published: 2025-06-12 20:18:48
Duration: 00:04:52
NRx Pharmaceuticals Announces Acquisition of Kadima Neuropsychiatry Institute and Plans to Launch $100 Million Psychiatry Clinic Network
NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, has acquired Kadima Neuropsychiatry Institute to establish a network of interventional psychiatry clinics. The subsidiary, HOPE Therapeutics, aims to open up to 30 clinics by 2025, with a projected $100 million run rate. NRx has also filed an ANDA for its preservative-free IV ketamine formulation, NRX-100, targeting the U.S. ketamine market and seeking to broaden its label for treating suicidal depression.
Published: 2025-06-05 18:24:54
Duration: 00:03:13
Empower Your Audience with Rythmia: Join the Affiliate Program Today!
Rythmia Life Advancement Center's new affiliate program targets wellness influencers, healers, and marketers to promote its life-changing experiences in Costa Rica. Offering competitive commissions and second-tier referral earnings, partners can share in Rythmia's mission of healing and transformation while earning income. Visit Rythmia's website for more details on this unique opportunity.
Published: 2025-06-03 18:28:25
Duration: 00:02:35
Cybin Inc. Secures U.S. Patent for CYB004 Anxiety Treatment Candidate
Cybin Inc. has obtained a U.S. patent for its CYB004 anxiety treatment candidate, extending exclusivity through 2040. CEO Doug Drysdale emphasized the potential of CYB004 to provide rapid-acting, short-duration treatment with a patient-friendly delivery system. The compound is in Phase 2 trials, projected to conclude by mid-2025, solidifying Cybin's position as a frontrunner in innovative mental health therapies.
Published: 2025-06-03 09:28:29
Duration: 00:01:57
Biotech Updates: Incannex Healthcare, Lophora, and NRx Pharmaceuticals
Stonegate Capital Partners provided an update on Incannex Healthcare Inc., reporting reduced expenses and strengthened financial position. Lophora initiated a Phase 1 trial for LPH-5 targeting CNS disorders, aiming to provide therapeutic benefits without hallucinogenic effects. NRx Pharmaceuticals announced a $10.3 million financing to expand its HOPE Clinic Network and advance FDA drug approval for neuroplastic therapies.
Published: 2025-05-28 22:50:47
Duration: 00:03:58
Advancement in PTSD Treatment: Silo Pharma's Nasal Spray Device Study
Silo Pharma Inc. is making strides in their PTSD treatment with a drug-device study on a microchip-enabled nasal spray system for SPC-15 in partnership with Resyca BV. The study aims to gather final device data for an FDA application, with CEO Eric Weisblum emphasizing the device's potential to bypass the blood-brain barrier for faster and safer therapeutic delivery. Additionally, the company is progressing with other SPC-15 studies, including a toxicology study and a large animal safety trial as requested by the FDA.
Published: 2025-05-21 14:31:19
Duration: 00:01:56
Advancements in Psychedelic Therapeutics: Cybin Inc., Republican Lawmakers, and Silo Pharma Inc.
Cybin Inc. is making progress in Phase 3 and Phase 2 trials for psychedelic therapeutics targeting mental health conditions, supported by FDA approval. Republican lawmakers like Rep. Morgan Luttrell are advocating for therapeutic use of psychedelics for veterans, while Silo Pharma Inc. recently closed a public offering to fund their research in psychiatric disorders and CNS diseases.
Published: 2025-05-20 12:47:06
Duration: 00:03:51
Biopharmaceutical Companies Silo Pharma Inc. and NRx Pharmaceuticals, Inc. Make Advancements in Drug Development and Financials
Silo Pharma Inc. has priced a public offering of common stock and warrants to raise $2 million, supporting its work on therapeutic treatments for psychiatric disorders and chronic pain. Meanwhile, NRx Pharmaceuticals, Inc. reported a Q1 net loss decrease, progress on ketamine and bipolar depression treatments, and funding for its psychiatry clinic subsidiary.
Published: 2025-05-16 22:08:26
Duration: 00:03:12
Advancements in Psychedelic-Based Therapeutics by Cybin Inc., Silo Pharma Inc., and NRx Pharmaceuticals Inc.
Cybin Inc. partners with Thermo Fisher Scientific for manufacturing of CYB003, a deuterated psilocin treatment for major depressive disorder. Silo Pharma Inc. collaborates with Veloxity Labs for bioanalysis supporting a PTSD treatment, while NRx Pharmaceuticals reports financial results post the acquisition of Kadima Neuropsychiatry Institute. All three companies focus on developing psychedelic-based therapeutics for mental health conditions.
Published: 2025-05-16 00:23:56
Duration: 00:05:27
Advancing Research on THC-Infused Beverages and Protecting Access to 7-OHM: Industry Initiatives in Focus
Love Yer Brain, part of Iconic Tonics, is collaborating with MoreBetter to study the impact of THC-infused beverages, aiming to provide insights into consumer preferences for alcohol alternatives. Meanwhile, the 7-HOPE Alliance has been established to protect legal access to 7-hydroxymitragynine (7-OHM) and promote responsible usage through science and advocacy efforts.
Published: 2025-05-07 22:58:50
Duration: 00:02:59
Innovations in Psychedelic Therapeutics and Pain Management at the Milken Conference
Cybin Inc. CEO Doug Drysdale will discuss drug development innovation and next-generation mental health treatments at the Milken Institute Global Conference. Meanwhile, Silo Pharma Inc. has reported positive preclinical data for its SP-26 Ketamine Implant for fibromyalgia and filed a patent application for SPC-14 targeting cognitive and neuropsychiatric symptoms in Alzheimer’s disease, showcasing advancements in pain management and cognitive health therapeutics.
Published: 2025-05-05 18:20:18
Duration: 00:04:02
Promising Results from Beckley Psytech's ELE-101 Phase 1 Trial for Major Depressive Disorder
In this episode, Atai Life Sciences co-founder and co-CEO Florian Brand discusses the promising initial results from Beckley Psytech's phase 1 trial of ELE-101 for major depressive disorder. ELE-101, an IV formulation of psilocin, aims to shorten treatment duration to two hours, with good tolerance and safety shown in phase one trials. The phase 2 trial is underway with data expected later this year. Brand also highlights the potential benefits of the two-hour treatment model for other compounds in development for depression treatment.
Published: 2024-06-26 07:33:22
Duration: 00:02:09
Exploring Ibogaine: A Breakthrough in Addiction Therapy with Deborah Mash, PhD
Join neuroscientist Deborah Mash, PhD, on 'Psychedelic Breakthrough Addiction Therapy' as she explores cutting-edge research on breakthrough addiction therapies, focusing on psychedelic medicines like Ibogaine. Dr. Mash, with thirty years of experience in addiction neuroscience, offers insight into groundbreaking therapies with the potential to transform lives. Tune in to CannabisRadio.com to learn more about the renaissance of psychedelic therapy for addiction treatment.
Published: 2024-06-25 15:23:52
Duration: 00:02:00
Exploring the Future of Psychedelic Therapy with Tryptamine Therapeutics Inc.
Join host Jonathan Jackson as he speaks with Tryptamine Therapeutics Inc. CEO Jason Carroll about the company's recent debut on the Australian Securities Exchange. Tryptamine Therapeutics is focused on developing an intravenous-infused psilocin formulation for psychedelic therapy, with core programs like TRP-8803 and TRP-8802 showing promising results in trials for conditions like fibromyalgia, IBS, and BED. Backed by a qualified Board and research partnerships, the company is set to begin groundbreaking clinical trials in Australia this quarter.
Published: 2024-06-05 13:07:25
Duration: 00:02:08